By Mary Brophy Marcus
MONDAY, Feb. 10, 2014 (HealthDay News) — A modern examination suggests that individuals at tall chance for heart infection who can’t take high-dose statin drugs to lower their cholesterol might benefit from a treatment combination that includes taking a low-dose statin.
Scientists at Johns Hopkins reviewed published inquire about to compare the benefits and hurts of a lower-intensity statin when combined with one of several other cholesterol-lowering medicines in grown-ups at high risk for heart illness.
Ponder author Dr. Kimberly Gudzune said combining a low-dose statin with either a so-called bile acid sequestrant or Zetia (ezetimibe) — both of which are solutions that too work to lower cholesterol levels — lowered “bad” (LDL) cholesterol. Taking a high-dose statin by itself also lowered LDL levels.
“At least in the brief term, this methodology appears to be as successful as the high-dose statin alone, although there were two major caveats: We do not know much almost side impacts and we don’t know around long-term effectiveness,” said Gudzune, an collaborator professor of medicine at Johns Hopkins.
She moreover said the researchers were not able to draw conclusions approximately mortality or heart problems such as heart assaults.
There was not sufficient evidence regarding LDL cholesterol decrease when it came to using a low-dose statin with fibrates, niacin or omega-3 fatty acids, Gudzune said. Fibrates can lower levels of blood fats known as triglycerides and can some of the time raise levels of “good” (HDL) cholesterol.
The review was published online Feb. 10 within the journal Annals of Inside Medication.
The American College of Cardiology and the American Heart Affiliation cholesterol guidelines recommend moderate- or high-intensity statin therapy for individuals whose restorative conditions or cholesterol levels put them at chance for heart disease — the leading cause of passing for both men and ladies within the Joined together States.
But a few patients do not react to tall doses of statins and a few suffer from side impacts, including muscle torment, Gudzune said.
“It doesn’t happen occasionally that patients come in and say, ‘I’m having muscle pains on this statin,'” she said. “So we wanted to audit the writing and offer assistance shed a little bit of light on it for those patients.”
Gudzune said they aren’t however beyond any doubt of the long-term benefits of combining low-dose statins and other medicines.
“Shockingly, we weren’t really able to examine the chance for [heart] events like heart assaults or strokes,” she said. “We aren’t sure in case it interprets into decreased [heart] risk.”
Dr. Chip Lavie is restorative executive of cardiac restoration and preventive cardiology at the John Ochsner Heart and Vascular Organized in Unused Orleans.
“This can be a decent paper,” Lavie said. “But I suspect that many clinicians … as of now know that a lower-dose statin combined with a second lipid agent — most know this best with ezetimibe — created at slightest comparable but probably slightly superior [comes about] … compared with lower-dose statins alone.”
Based on the foremost later rules, Lavie said, doctors should try to induce patients to endure the proven treatments some time recently resorting to other less demonstrated “but possibly exceptionally effective treatment approaches.”